- /
- Supported exchanges /
- NASDAQ /
- LAB.NASDAQ
Standard Biotools Inc (LAB NASDAQ) stock market data APIs
Standard Biotools Inc Financial Data Overview
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Standard Biotools Inc data using free add-ons & libraries
Get Standard Biotools Inc Fundamental Data
Standard Biotools Inc Fundamental data includes:
- Net Revenue: 156 M
- EBITDA: -114 313 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-10-30
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Standard Biotools Inc News
Is Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5?
We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Standard BioTools Inc. (NASDAQ:LAB) ranks among the best NASDAQ stocks under $5. Job Market Cools ...
11 Stocks Under $5 With High Potential
In this article, we will take a look at 11 stocks under $5 with high potential. To skip our analysis of the recent market activity, you can go directly to see the 5 Stocks Under $5 With High Potential...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, SMMF, RPT, LAB
NEW YORK, Nov. 18, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results
Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against financial objectivesPlanned merger with SomaLogic activates strategic M...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.